Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

  • Revenue in CHF (TTM)63.28bn
  • Net income in CHF12.42bn
  • Incorporated1966
  • Employees103.61k
  • Location
    Roche Holding AGGrenzacherstrasse 124BASEL 4058SwitzerlandCHE
  • Phone+41 9 732354295
  • Websitehttps://www.roche.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ROG:SWX since
announced
Transaction
value
Good Therapeutics IncAnnounced07 Sep 202207 Sep 2022Announced-11.91%250.00m
Data delayed at least 15 minutes, as of Jun 08 2023 15:34 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bayer AG49.18bn2.96bn49.89bn101.74k16.861.255.371.013.093.0951.3941.600.40261.673.46498,071.402.44-1.113.30-1.4559.5458.986.05-3.040.75874.950.5135--15.107.70315.005.024.50-2.72
GSK plc32.94bn4.91bn63.82bn69.40k12.484.778.031.941.103.647.522.890.39231.513.84419,092.206.456.399.8210.4270.4269.5516.4415.900.6949.710.648993.3718.74-0.577851.7310.270.5035-5.53
Sanofi SA45.00bn8.14bn116.76bn91.57k14.29--11.392.596.656.6536.84--------504,504.60--5.80--7.0269.9368.4918.2417.00--102.64--59.8415.864.6234.5217.282.393.28
Novartis AG47.46bn6.40bn203.83bn103.00k30.263.9617.744.292.962.9621.9022.590.43912.036.02466,647.005.929.097.9511.7771.0970.9813.4823.680.793112.260.358659.94-2.153.60-71.05-1.493.093.79
AstraZeneca plc39.93bn4.28bn206.30bn83.50k48.466.3321.825.172.432.4322.6018.570.44521.354.62422,245.704.782.636.313.6280.6378.9910.746.350.69596.820.468187.0718.5314.572,835.716.639.681.13
Roche Holding AG63.28bn12.42bn235.43bn103.61k18.748.2213.553.7215.3615.3678.3235.030.70132.275.65610,743.8015.0016.2125.3125.3370.7571.0721.3822.620.925619.250.441959.330.76433.49-10.837.262.632.74
Novo Nordisk A/S24.62bn7.99bn245.26bn57.09k40.6330.7527.689.9626.8826.8882.7135.520.84221.294.343,461,659.0027.3429.8355.6758.5884.2283.7632.4732.860.669416.840.242145.8825.689.6416.277.8111.279.57
Data as of Jun 08 2023. Currency figures normalised to Roche Holding AG's reporting currency: Swiss Franc CHF

Institutional shareholders

15.21%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 05 May 202321.04m2.99%
Norges Bank Investment Managementas of 31 Dec 202220.23m2.88%
UBS Asset Management Switzerland AGas of 02 May 202313.61m1.94%
BlackRock Fund Advisorsas of 04 May 202312.62m1.80%
Credit Suisse Asset Management (Schweiz) AGas of 30 Apr 20239.67m1.38%
Z�rcher Kantonalbank (Investment Management)as of 31 Jan 20236.97m0.99%
BlackRock Advisors (UK) Ltd.as of 04 May 20236.36m0.91%
FIL Investment Advisors (UK) Ltd.as of 30 Apr 20235.81m0.83%
Massachusetts Financial Services Co.as of 30 Apr 20235.47m0.78%
Alecta Pension Insurance Mutualas of 31 Dec 20195.09m0.73%
More ▼
Data from 31 Dec 2022 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.